drugset
drugset / Trial / NCT00374296

MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease

NCT00374296 ↗

Phase 2 Terminated 35 enrolled Mirati Therapeutics Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

In this study, MGCD0103, a new anticancer drug under investigation, is given three times per week to elderly patients with previously untreated acute myelogenous leukemia/high risk myelodysplastic syndrome or adults with relapsed/refractory disease.

Timeline

Start
2006-09
Primary completion
2008-09
Completion
2008-09

Outcome

Outcome not reported

Stopped: “The Clinical Development Program for MGCD0103 is being re-evaluated”

Drugs

EvaluationDrugModalityDoseRoute
Subject Mocetinostat Small molecule — Oral

Indications

acute myeloid leukemia myelodysplastic syndrome